SCHEDULE: Humacyte, Inc. and Fresenius Medical Care Amend Distribution Agreement

Humacyte, Inc. and Fresenius Medical Care Holdings, Inc. have amended their distribution agreement, granting Humacyte exclusive global rights to distribute Symvess(R) outside the U.S. in exchange for low-single-digit royalties.

Summary

• This filing is an amendment (Amendment No. 8) to a Schedule 13D, originally filed by Fresenius Medical Care Holdings, Inc. (FMCH) and Fresenius Medical Care AG (FME AG) regarding their beneficial ownership of Humacyte, Inc. common stock.
• The primary update concerns a Third Amendment to the 2018 Distribution Agreement between FMCH and Humacyte, entered into on April 21, 2026.
• Under the amended agreement, Humacyte now holds exclusive rights to distribute Symvess(R) (acellular tissue engineered vessel) outside of the United States.
• FMCH will receive low-single-digit royalties on net sales of Symvess(R) in these ex-U.S. territories.
• The existing terms for Symvess(R) distribution within the U.S. remain unchanged.
• This reversion of ex-U.S. distribution rights to Humacyte is part of FME AG's 'Legacy Portfolio Optimization program'.
• FMCH and FME AG collectively beneficially own 18,312,735 shares of Humacyte's common stock, representing 8.4% of the class.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral development. While Humacyte gains global rights, the financial implications are not fully detailed, and the royalty structure for Fresenius Medical Care is modest.

Positives

• Humacyte gains exclusive global distribution rights for Symvess(R), potentially increasing its market reach and control over international sales.
• The amendment is part of FME AG's strategic 'Legacy Portfolio Optimization program', suggesting a focus on streamlining operations.
• FMCH and FME AG continue to hold a significant stake (8.4%) in Humacyte, indicating ongoing strategic interest.

Negatives

• Humacyte will now be responsible for all ex-U.S. distribution of Symvess(R), which may increase operational complexity and costs.
• FMCH will receive only low-single-digit royalties, which could be a reduced revenue stream compared to previous arrangements.
• The filing does not provide specific financial projections for the impact of this change on Humacyte's revenue or profitability.

Risks

• Humacyte's ability to effectively manage and expand ex-U.S. distribution of Symvess(R) is a key risk.
• The success of the 'Legacy Portfolio Optimization program' for FME AG is not detailed, but such programs can involve divestitures or restructuring that may have unforeseen consequences.
• The filing does not detail any specific risks associated with the Symvess(R) product itself or its market adoption outside the U.S.

Future Outlook

The amendment to the distribution agreement signifies a strategic shift for Humacyte, granting it exclusive global rights for Symvess(R) distribution outside the U.S. This move is part of Fresenius Medical Care's portfolio optimization. The future outlook for Humacyte will depend on its ability to leverage these new rights and manage international expansion, while Fresenius Medical Care will receive ongoing royalties.

Management Comments

• The amendment is part of FME AG's 'Legacy Portfolio Optimization program'.
• Existing terms related to the U.S. distribution of Symvess(R) remain unchanged.

Industry Context

StockSavvy.ai notes that this amendment reflects a common trend in the life sciences and medical device industries where companies strategically adjust distribution rights to optimize market access and focus on core competencies. Humacyte's acquisition of global rights for Symvess(R) positions it for potentially greater control over its international commercialization strategy, while Fresenius Medical Care's royalty-based arrangement aligns with its portfolio optimization goals.

Related Party Transactions

• The amendment to the Distribution Agreement between FMCH and Humacyte is a related party transaction, as FMCH and FME AG are significant beneficial owners of Humacyte.

Stakeholder Impact

• Shareholders of Humacyte: May benefit from increased control over global market strategy for Symvess(R), but also face increased responsibility for international operations. The royalty structure for Fresenius Medical Care could impact future revenue recognition for Humacyte.
• Shareholders of Fresenius Medical Care: May see a streamlined portfolio as part of the 'Legacy Portfolio Optimization program', with ongoing, albeit potentially modest, royalty income from Symvess(R) sales.
• Employees of Humacyte: May see increased workload and responsibility related to international sales and distribution.
• Creditors of Humacyte: The impact is indirect, depending on Humacyte's ability to successfully commercialize Symvess(R) globally.

Next Steps

• Humacyte will assume exclusive responsibility for the distribution of Symvess(R) outside the U.S.
• Fresenius Medical Care will begin receiving low-single-digit royalties on net sales of Symvess(R) outside the U.S.

Key Dates

Keywords

Humacyte, Fresenius Medical Care, Distribution Agreement, Symvess, Schedule 13D, Amendment, Tissue Engineered Vessel, Royalty, Ex-U.S. Rights, Corporate Governance